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The Impact of Migraine on Health Status
Marie-Louise Essink-Bot, MD; Leona van Royen, MSc; Paui Krabbe, MSc; 
Gouke J. Bonseí, MD, PhD; Frans FH Rutten, PhD
Problems.—What is the effect of migraine on health status, 
defined as the patient's physical, psychological, and social 
functioning? And, suppose that the health status of migraine 
sufferers appears to be impaired, to what extent is this a 
consequence of migraine-associated comorbidity rather than 
of migraine itself?
Methods.—A group of 846 migraineurs, selected from the 
general population following IHS criteria, and a control group 
were surveyed with the Medical Outcomes Study 36-item 
Short-Form Health Survey, Nottingham Health Profile, EuroQol 
instrument, and the COOP/WONCA charts. Questions on 
demographic characteristics and comorbidîty were included.
Results.—The health status of migraineurs appeared to be 
significantly impaired in comparison to the control group. 
Because statistical significance is distinct from relevance, ef­
fect size estimators were employed. Although the direction 
of the differences indicated consistently a worse health status 
of the migraineurs, regardless of the instrument used, the sizes 
of the differences were small to medium. Self-reported co- 
morbidity, especially depression, was more prevalent in the 
migraine group. However, this offered only a partial explana­
tion for the impaired health status of the migraine group.
Conclusions.—Migraine has an independent moderately 
deteriorating effect on the daily functioning of individuals.
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The burden of migraine, a chronic, attack-wise, 
and presumably disabling disease, should not be 
underestimated. The reported 1-year prevalence in 
adults exceeds 10%, with a male to female ratio of 
about 1:2 to 3.1 People in the age range 15 to 55 
years are predominantly afflicted, ie, those in the 
work force. Long-term consequences of migraine 
may result from interference of frequent attacks 
with daily life, thus precluding optimal function­
ing. We designed a study to quantify the burden 
of migraine both in terms of its economic conse­
quences and in terms of its impact on health status. 
The economic part of the study, published in de­
tail elsewhere, showed that direct costs of migraine 
in the Netherlands accounted for 0.3% of the total 
health care costs in 1988, 80% of which could be 
attributed to "alternative" medical practice. Indi­
rect costs, due to absence from work and reduced 
productivity, were estimated to amount to at least 
542 million Dutch guilders per year (in 1988, $1 = 
1.9 guilders)2.
Health status, the focus of the present paper, is 
defined as physical, psychological, and social func­
tioning. Osterhaus and Townsend concluded from 
a survey of 845 migraineurs (meeting IHS criteria3) 
using the Medical Outcomes Study 36-item Short- 
Form Health Survey (SF-36) that "although mi­
graineurs may be physically able to function, they 
function behaviorally at a level well below their 
physical capabilities, and for some domains even 
worse than patients suffering from arthritis, gas­
trointestinal disorders or diabetes."4 Solomon et 
al assessed the health status of 208 patients attend­
ing a headache center with the Medical Outcomes 
Study 20-item instrument (MOS-20). The authors 
conclude "that chronic headache disorders are 
associated with significant limitations in all meas­
ured dimensions of patient well-being and func­
tioning when compared to patients with no chronic 
condition; and that patients with chronic headaches 
have a level of function worse than that of patients 
suffering from diabetes, arthritis, depression, and
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back problems."5 Jenkinson reported the results 
of interviewing 80 women attending a migraine 
outpatient clinic (diagnosed as suffering from 
migraine by a neurologist) with the Nottingham 
Health Profile (NHP) and the General Health Ques­
tionnaire (GHQ; a screening instrumentfor nonpsy- 
chotic psychiatric disturbance).6 General Health 
Questionnaire scores were indicative of mood 
disturbance in no less than 41% of the subjects. In 
a Dutch study among elderly patients (age range 
55 to 79 years), only 9% of those who stated they 
suffered from "migraine or severe headache" 
reported physical limitations, and 10% gave a 
negative evaluation of their general health. How­
ever, 45% regarded their psychological well-being 
as being impaired by their headache complaints.7 
Overall, these studies are indicative of a worse 
functioning of migraine sufferers. However, con­
trolled studies, enabling a comparison between 
migraine sufferers and non-afflicted subjects and 
an estimation of the size of the effect of migraine 
on health status, are not known to us.
It has been recognized that migraine often 
occurs in association with other conditions, like 
mood disturbances (depression, anxiety),8'10 
allergic phenomena (atopy, asthma, food  
allergy),11*12 and vasospastic disorders (Raynaud's 
phenom enon).13'15 This higher prevalence of 
comorbidity was confirmed in a recent Dutch 
survey on socioeconomic health inequalities in a 
representative sample of the general population 
(n=15973; age range 15 to 64years). The prevalence 
of self-reported migraine (no check on IHS criteria) 
was 12% for women and 5% for men. Women with 
migraine reported no other chronic condition in 
39% of cases, while 15% reported two or more; for 
women without migraine these figures are 60% and 
5%. The largest difference in prevalence of a 
specified chronic condition was for "depression/ 
nervous exhaustion" (22% for women with 
migraine, 6% for women without migraine). Similar 
figures held for men with and without migraine in 
this study (K. Stronks, Department of Public Health, 
Erasmus U niversity  Rotterdam; personal 
communications, 1994).
With regard to the causal relationship between 
migraine and comorbid conditions, several authors 
have proposed a common disposition or a com­
mon pathogenetic defect.12'16 Information about the 
consequences of the higher prevalence of co­
morbidity in migraine sufferers is scarce. In par­
ticular, the relative contribution of migraine and 
other conditions to the lower level of functioning 
by migraine patients has not been investigated 
previously.
In the present study, the health status of mi­
graine patients is compared with that of a control 
group. We intend to answer the following ques­
tions: (1) What is the health status of migraine 
sufferers compared with a control group that is 
comparable in age, sex, and employment status? 
(2) Are the differences between migraineurs and 
controls consistent if measured with different 
generic instruments? and (3) What is the relative 
contribution of migraine and associated comorbid­
ity, especially self-reported depressive disorders, 
to the impaired health status of migraine suffer­
ers?
METHODS
Samples.—Migraine patients were selected from a series 
of face-to-face interviews with a representative sample of the 
Dutch general population (n = 10480), avoiding the selection 
of only severe cases who sought medical care, during the 
period October 1992 to February 1993. Subjects were included 
as migraine patients if they met the IHS criteria3 and had expe­
rienced at least one attack of migraine during the 12 months 
prior to the interview. Nine hundred ninety-two migraine suf­
ferers met these criteria (1-year prevalence, 9.5%). Of these 
sufferers who were all invited to participate in a second study, 
viz, the actuai investigation on health status and (in)direct costs, 
85% (n « 846) actually agreed to cooperate.
The control group was selected from the subjects in the 
survey who did not meet the criteria for migraine by frequency 
matching to the migraine group on 5-year age class, sex, and 
employment status.
Instruments.—Generic instruments for health status assess­
ment measure basic values (physical, psychological, and so­
cial functioning) which are relevant for everyone's health 
status.17 There is general agreement that the primary source 
for such information is to be found in the subjects themselves. 
Generic questionnaires are nondisease specific, enabling 
comparison of health status data across the borders of speci­
fied diagnoses. A combination of four generic questionnaires, 
the SF-36, the NHP (Dutch adaptation), the EuroQol descrip­
tive instrument, and the COOP/WONCA charts, was applied to 
investigate whether differences between migraineurs and 
controls were consistent if measured with different instru­
ments. Data were also analyzed to compare testing properties 
of these questionnaires.
The SF-36 was developed in the United States from 
the Medical Outcome Study General Health Survey Instru­
ment.17’20 It consists of 36 items, assigned to the domains of 
physical functioning (10 items), social functioning (2), role 
limitations - physical problems (4), role limitations - emotional 
problems (3), mental health (5), vitality (4), pain (2), general 
health perceptions (5), and health change (1). The numbers of 
response categories per item range from 2 to 6. The end score 
is an eight-dimensional profile. The Dutch version we used 
was developed as a part of the IQOLA project, which aims to 
translate, validate, and normalize the SF-36 in a range of 
languages and cultural settings.21
The NHP was developed during the 70s in the United King­
dom as a measure for perceived health, to be used in popula­
tion surveys.22 Part 1 of the NHP consists of 38 dichotomous 
items, covering the domains of physical mobility (8 items), pain 
(8), energy (3), sleep (5), social isolation (5), and emotional 
reaction (9). Part 2 consists of seven items on problems be­
cause o f health in seven specified areas of life. The Dutch ver­
sion, the NHP-DA, we used has been tested in several patient 
populations.23’24
The EuroQol classification consists of five items (mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depres­
sion), each following the general form: no problems - some
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problems - extreme problems.25 Additionally, evaluation of 
one's own health is assessed with a visual analogue scale 
ranging from 0 {worst imaginable health state) to 100 (best 
imaginable health state). The EuroQol instrument was devel­
oped by the International EuroQol Group as a standardized, 
nondisease-specific measure for description of health status. 
EuroQol health state descriptions can be linked directly to 
empirical valuations of health states by the general popula­
tion, which makes it especially interesting for the economic 
evaluation of medical interventions.
The COOP/WONCA charts were developed to assess health 
status of patients in primary care.26 There are six charts, cov­
ering the areas of physical fitness, feelings, daily activities, 
social activities, change in health and overall health. The lev­
els on the scales are illustrated with pictograms.
Comorbidity was assessed by the list of chronic conditions 
as included in the Dutch Health Interview Survey of the Dutch 
Central Bureau of Statistics. This list counts 28 conditions in 
lay terms {like "asthma, chronic bronchitis, orCOPD", "diabe­
tes” , "varicose veins"). Respondents are asked to indicate for 
each condition whetherthey have it now or if they have had it 
in the year prior to assessment.
Questionnaire Layout and Mailing Scheme.—We used four 
different questionnaires, two for the migraine group and two 
for the control group. All versions contained the SF-36, Eu­
roQol, and questions relating to comorbidity and demogra­
phy. The two migraine versions differed from each other, one 
containing the COOP/WONCA charts, the other the NHP. The 
two control group versions differed in the same way. Both 
migraine versions contained additional questions on the 
number of attacks during the year prior to assessment and on 
medical consumption.
Questionnaires were sent by mail in June 1993, with re­
minders 2 weeks (a postcard) and 5 weeks (a complete ques­
tionnaire) later.
Analysis.—To investigate any selectivity of response, non­
response analyses were conducted by comparing and testing 
(chi-square test) the distributions of age, sex, social class, and 
degree of urbanization of addressees and respondents.
Scores were declared as missing values if nothing was filled 
in or if ambiguous information was provided. Because of 
generally low missing value rates, we did not impute con­
structed values for missings. Scale scores for the SF-36 and 
NHP were based on complete records only.
The Mann-Whitney U test was applied for testing differ­
ences in scores of continuous nonnormally-distributed vari­
ables between migraine group and controls. To avoid the ef­
fect of multiple testing, P<  0.01 was regarded as statistically 
significant. Given the large sample size, statistical significance 
may be misleading: relatively small mean differences will 
achieve conventional levels of statistical significance without 
representing meaningful differences in functioning. We em­
ployed an estimator of effect size d for continuous variables, 
which relates the differences in mean scores to the dispersion 
of the scores. A d  *  .2 indicates a small effect, a d  = .5 a me­
dium effect, and a d=  .8 a large effect.27
The chi-square test was used to test fo r proportional differ­
ences in contingency tables, Again, P<0.01 was regarded as 
statistically significant. The effect size estimator IVfor contin­
gency tables has a different interpretation: .1 indicates a 
small effect, W=  .3 a medium effect, l/V= .5 a large effect27
Multiple classification analysis (MCA) was applied to ex­
plore the relative effects on health status of migraine and as­
sociated comorbidity.26*29 In essence, MCA is multiple regres­
sion analysis using dichotomous predictor (or explanatory) 
variables. We used "migraine - yes/no", "depression - yes/no" 
and "diseases of the skin - yes/no" as predictor variables. The 
choice of the latter two conditions was based on significant 
differences of their prevalences in the migraine group and the 
control group. The scale scores of the SF-36, NHP, and Eu­
roQol (valuation of one's own health) that showed the largest 
differences between the migraine group and the control group
were used as dependent (or explained) variables in separate 
MCAs. It can be argued that log-linear analysis would be more 
appropriate, because for MCA a continuous and normal distri­
bution of the dependent variable is required. Application of 
log-linear analysis did not change the conclusions. We have 
chosen to present MCA results as they are easier to interpret.
RESULTS
Response.—The questionnaire was mailed to 
846 migraine sufferers as identified by the diag­
nostic interview. Sixty-five of them returned it, 
indicating they did not have migraine. A number 
of migraineurs, as classified by the diagnostic inter­
view, probably did not label their headaches as 
migraine themselves, After exclusion of these 65 
and after correction for wrong addresses, the crude 
response rate was 63%. Of these, 90% were us­
able (n=436). There were no significant differences 
in response rates between the two migraine groups 
(questionnaire with COOP/WONCA charts or NHP 
respectively). Eight hundred forty-three question­
naires were mailed to the control group. After 
correction for wrong addresses, the crude response 
rate was 72%. Ail but 10 were usable (n=575). As 
in the migraine group, there were no significant 
differences in response rates between the two 
control groups.
Due to the different composition of the ques­
tionnaires, the following numbers per instrument 
were available for analysis: SF-36 and EuroQol, 436 
in the migraine group and 575 in the control group; 
for NHP-DA, 225 in the migraine group and 287 in 
the control group; for COOP/WONCA 211 in the 
migraine group, and 288 in the control group.
The nonresponse analyses did not show signifi­
cant differences between addressees and respon­
dents in either the migraine group or the control 
group, suggesting no selective nonresponse.
Respondents' Characteristics.— Demographic 
characteristics and data relating to the prevalence 
of self-reported comorbidity are presented in Table
1. The differences between the respondents in the 
migraine group and the controls were not signifi­
cant for sex distribution, age, employment status, 
or educational level. However, after exclusion of 
"migraine" and "severe headache," the respon­
dents in the migraine group reported significantly 
more chronic conditions now or in the past year. 
Especially "diseases of the skin/eczema" (14% in 
the migraine group, 9% in the control group) and 
"depression/nervous exhaustion" (29% in the 
migraine group, 16% in the control group) were 
more prevalent in the migraine population.
The migraine patients reported an average 
number of 13 attacks of migraine during the past 
12 months (41%, 4 or fewer; 18%, 5 to 9; 23%, 10 to 
19; 18%, 20 or more). About 70% of the migraine
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Table 1. — Respondents' Characteristics
Feature
Migraine Group 
(n=436)
Control Group 
(n-575)
Sex {% female)
Age, y (mean [SD]) 
Employment status 
{% with paid job) 
Education 
Low (%)
Medium (%)
High (%)
Comorbidity (excluding 
migraine and headache)
0 conditions (%)
1 condition (%)
2 conditions (%)
> 2 conditions (%) 
Number of conditions 
(mean[SD])
84
40(13)
47
34
38
28
80 
41 (14)
44
31
38
31
29
31
22
19
1.50(1.54)
43
27
14
16
1.15(1.40)
patients consulted a general practitioner for their 
headaches. Only half of them did so during the past 
year, and only 6% of them consulted a neurologist 
during that year.
Health Status: SF-36.—The results of the SF-36 
(see Table 2 and Figure 1) show statistically sig­
nificant worse functioning for the migraine group 
in all eight domains. The differences are small to 
medium-sized. The differences between migraine 
patients and controls are the largest for pain, so­
cial functioning, vitality and role limitations due to 
physical problems.
NHP-DA.—The NHP-1 results (Table 3 and Fig­
ure 2) show significant results only for the scales 
"energy" and "emotional reaction." The effect 
sizes are small. The results forthe NHP-2 (Table 4)
physical emotional health
Fig 1.—SF-36 scores. Migraine group (n=436) and control group 
(n=575).
Table 3 — Nottingham Health Profile - DA (Part 1)
Dimensions*
Migraine
Group
n=225 
mean (SD)
Control 
Group 
n=287 
mean (SD)
MWU
Pvalues
Effect Size 
(W)**
Mobility 9(15) 6(13) .013 .12
Energy 20 (29) 12 (24) .001 .15
Pain 11 (21) 7(16) .029 .12
Sleep 13(24) 11(22) .221 .07
Social isolation 8(18) 5(14) .031 .10
Emotional reaction 12(18) 8(17) <.001 .21
* 0 Indicates optimal level, 100 indicates worst level,
** W - ,1, small effect; W*.3, medium effect; W= .5, large effect. Wwas 
used here instead of d because of nonnormally or noncontinuously distrib­
uted data.
Table 2. — SF-36 Results
Migraine Control
Group Group
°1n=436 n=575 MWU Effect
Dimensions* mean (SD) mean (SD) P/values Size (d)** 10-
Physical functioning 85(19) 86 (21) .006 .07 20-
Social functioning 76 (21) 85 (21) <.001 .39*** 30-
Role limitations
(physical) 63 (40) 77 (36) <.001 .34*** 40-
Role limitations
50-
(emotional) 75 (38) 81 (34) .007 .17***
Mental health 72 (19) 77 (18) <.001 .25 60-
Vitality 62 (19) 68(18) <.001 .35
70-Pain 65 (22) 78 (22) <.001 .57
General health ao-
perceptions 68 (20) 73 (18) <.001 .29
* 0 indicates poor functioning, 100 indicates optimal functioning.
** d=.2, small effect; d= .5, medium effect; d= .8, large effect,
* * *  Because of nonnormal or noncontinuous distribution of the data of 
these scales, use of effect size Wis generally more appropriate. However, 
computation of Wdid not change the conclusions.
90-
100
■e migraine
controls
--------------------------------------1—
emotion
— I—
social sleep pain energy mobility
Fig 2.— NHP-DA scores. Migraine group (nr225) and control 
group (n=287).
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Table 4. — Nottingham Health Profile - DA {Part 2)
Migraine Control
Group Group
n=225 n=287 Chi-square Effect Size
(%  yes) (%  yes) P values (W)*
Health Causes Problems For
Paid job 22 11 .34 .14
Household work 33 15 <.001 .21
Social life 25 11 <.001 .18
Home life 29 8 <.001 .27
Sex life 21 10 <.001 .15
Hobbles 22 14 .025 .10
Holidays 7 5 .335 .04
*W= .1, smail effect; .3, medium effect; W= ,5, large effect.
show that migraine causes significant problems for 
household work, social life, home life, and sex life; 
the largest effects are medium-sized (household 
work and home life).
EuroQol.—Table 5 shows the EuroQol classifi­
cation scores. The scores of the migraine group 
are indicative of significantly worse health status 
of the migraine group for the items "usua! activi­
ties/' "pain/discomfort" and "anxiety/depression" 
as well as for the "valuation of own health." The 
effect sizes of these differences are small to m e­
dium.
Table 5. — EuroQol Classification Scores
Migraine Control
Group (% ) Group {% ) Chi-square Effect Size
Items n=436 n-575 P/values (MO**
Mobility*
No problems 83.0 87.4 .051 .06
Some problems 16.3 12.4
Confined to bed 0.7 0.2
Self-care
No problems 97.2 98.0 .386 .03
Some problems 2.8 2.0
Unable to 0 0
Usual activities
No problems 72.4 83.3 <.001 .15
Some problems 26.4 14.8
Unable to 1.2 1.9
Pain discomfort
None 49.5 67.4 <.001 ,19
Some 46.6 31.2
Extreme 3.9 1.4
Anxiety depression
None 73.0 85.3 <.001 .15
Some 24.6 13.7
Extreme 2.5 1.1
Valuation of own health
0-100 mean (SO) 77(17) 83 (15) <.001 .38 (c0‘ * *
* 1 = optimal level, 3 = worst leveL
** W« .1, small effect; W* .3, medium effect; .5, large effect. 
* * *  .2, small effect; d= .5, medium effect; d* .8, large effect.
COOP/WONCA Charts.—The scores of the 
migraine group and the control group for the 
COOP/WONCA charts are shown in Table 6. The 
lower level of functioning of the migraine group is 
significant for two of six items, viz, daily activities 
(small effect) and overall health (medium effect).
Table 6. — COOP/WONCA Charts
Migraine Control
Group Group
n=211 n=288 MWU Effect
Items* mean (SD) mean (SD) P/values Size (d)**
Physical fitness 1.7 (1.0) 1.7 (1.1) .981 .00
Feelings 2.0 (1.0) 1.8 (0,9) .031 .22
Daily activities 1.9 (0.9) 1.6 (0.8) <.001 .29
Social activities 1.6 (0,8) 1.5 (0.8) .210 .19
Change in health 2.6 (0.8) 2.7 (0.8) .098 .10
Overall health 2.9 (0.9) 2.5 (1.0) <.001 ,39
* 1 = optimal level, 5 = worst level.
* *  .2, small effect; tf» .5, medium effect; d= .8, large effect.
Consequences of Comorbidity on Functioning 
of Migraine Patients.—The results of the study as 
described above showed worse functioning of the 
migraine group and a higher prevalence of self- 
reported comorbid conditions, especially "depres­
sion/nervous exhaustion" and "diseases of the 
skin/eczema." We examined the extent to which 
the impaired health status of the migraine suffer- 
ers could be attributed to migraine and to the most 
relevant comorbid conditions respectively. We did 
seven consecutive MCAs with painiSF'36), role limi­
tations physical(SF‘36), vitalityiSF*36), social function- 
ingiSF’36Jf general health perceptions(SF36)f energy(NHP) 
and valuation of own health(EuroQo,) as dependent 
variables respectively. Each of these MCAs showed 
significant coefficients for the explanatory variables 
"migraine" and for "depression" (P <  0.001), but 
insignificant coefficients for "diseases of the skin." 
The effect of "depression" was larger than the 
effect of "migraine," except for pain(SF*36). For some 
of the dependent variables (social functioningiSF" 
36), valuation of own healthiEuroQo11, role limitations- 
physical(SF_361, the interaction effect (migraine* 
depression) was significant (P <  .01, .01, and .02 
respectively), which indicates that the detrimental 
effect of the presence of both conditions on the 
dependent variable is larger than the additive ef­
fect of each of them.
COMMENTS
Our study shows that the health status of mi- 
graineurs is significantly impaired in comparison 
with a control group. The direction of the differ­
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ences consistently indicated a worse health status 
of the migraineurs, regardless of the instrument 
used. The fact that these differences were found 
with generic instruments, which are meant for 
assessment of health status ranging from "very 
bad" to "very good" is an indication that they are 
real differences. Because statistical significance is 
distinct from relevance, the differences between 
the migraine group and the control group were 
placed in perspective by effect size estimators. The 
sizes of the differences were small to medium. This 
finding has face validity; despite the impaired 
functioning of migraineurs, migraine is generally 
not a severely incapacitating condition like, for 
example, end-stage cancer. Comparison of the 
results of the health status assessments of the 
migraine sufferers with published results for other 
patient groups are likely to be flawed to some 
extent because of different composition of the 
groups regarding, for example, age and sex. With 
this precaution in mind, the NHP-DA scores of the 
migraine group in our study are in the same range 
as those of a group of Dutch patients with mild 
airflow obstruction.30
The largest differences between migraine suf­
ferers and controls were observed in the areas of 
pain(SF'36), and to a lesser extent pain/dis­
co mfort(EuroQol), role limitations - physicaliSF'36), 
household work(NMP'2); social functioning^'361, home 
|jfe(NHP-2>; vita I ityiSF36> and energy(NHP|, overall
health(C00P>, and valuation of own healthtEuroQol). The 
unexpected lack of a difference on painiNHPi can be 
attributed to the fact that many of the items of this 
scale relate to pain when walking or standing; 
pain(SF'36) refers more generally to the amount of 
bodily pain experienced in the past 4 weeks and 
its interference with normal work.
Additionally, we explored whether (self-re­
ported) depressive disorders and diseases of the 
skin, which have a higher prevalence among mi­
graineurs, could explain their health status impair­
ment. The effect of migraine on health status 
remained significant after correction for these two 
conditions, which means that migraine has a con­
sistent independent, though moderate, impact on 
health status.
The relevance of the presented results is two­
fold. First, the impairment of the overall function­
ing of migraine patients has been quantitatively 
documented. Secondly, we showed the effect of 
migraine on health status to be independent of two 
relevant comorbid conditions, viz, self-reported 
depression and diseases of the skin. The impact of 
migraine on health status justifies the continuing 
search for cost-effective remedies for this condi­
tion. Treating migraine will probably improve the
sufferer's functioning. However, migraineurs are 
at a greater risk of depression and other comorbid 
conditions, some of which have an additional det­
rimental effect on health status. Clinical awareness 
may result in a higher opportunity of treating these 
associated conditions, with probably additional 
positive effects on the daily functioning of migraine 
sufferers.
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